Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently…
An institutional-grade, numbers-driven thesis on AXSM — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Axsome Therapeutics, Inc. (AXSM) 57/100 with a 12-month base-case forecast of $265.29 — +24.7% versus the current price of $212.74. Axsome Therapeutics, Inc. trades at $212.74 in the Healthcare sector, with a market capitalisation of $10.95B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for AXSM is $265.29, implying +24.7% versus the current price. The model's 12-month scenario range runs from $338.71 (bear) to $384.62 (bull), with a base case of $355.43.
On the fundamentals, Axsome Therapeutics shows a P/E of -57.0, trailing revenue of $638.5M, revenue growth of +65.5% YoY. This page also tracks AXSM's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
AXSM currently carries a TradersQuant composite score of 57/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $265.29 implies +24.7% from $212.74. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for AXSM is $265.29, about +24.7% versus the latest price of $212.74. Consensus is based on 26 analysts.
TradersQuant's 12-month model forecast for AXSM is a base case of $355.43, ranging from $338.71 (bear) to $384.62 (bull), an expected return of +67.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for AXSM over the next 12 months is $355.43 in the base case (bear $338.71, bull $384.62), versus today's price of $212.74. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for AXSM — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates AXSM's fair value at $265.29, implying +24.7% of expected upside versus the current price.
Axsome Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
